The effect of eldecalcitol on balence and strength in women with osteoporosis

Study Type: Therapy
OE Level of Evidence: 2
Journal Level of Evidence: N/A
50 women with osteoporosis were randomized to weekly alendronate plus daily eldecalcitol, or weekly alendronate alone. The purpose of this study was to assess muscle strength and balance after 6 months of treatment in both groups. The within-group evaluation Please login to view the rest of this report. Please login to view the rest of this report.
Funding: Not Reported
Conflicts: None disclosed
Why was this study needed now?
Osteoporosis is a bone condition characterized by low bone mineral density, with sufferers at increased risk of fracture. Bisphosphonates, such as alendronate, are used in the management of patients with osteoporosis to increase BMD. Nevertheless, patients with osteoporosis often demonstrate below average balance, with falls a primary concern within this population. Vitamin D3 (eldecalcitol) has been used in the preventive management of fractures in patients with osteoporosis, and there is current interest in the effects of eldecalcitol on balance and strength in these individuals. However, randomized controlled trials evaluating these outcomes are scarce.
What was the principal research question?
In postmenopausal women with osteoporosis, what is the effect of daily eldecalcitol, in addition to weekly alendronate, on muscle strength and balance, assessed after 6 months of treatment?
Population: 50 women, aged 63-86, with osteoporosis (Japanese Society for Bone and Mineral Research criteria).
Intervention: Eldecalcitol group: Patients received eldecalcitol 0.75ug/day, in addition to alendronate 35mg/week, for 6 months.
Comparison: Control group: Patients were treated with alendronate 35mg/week for 6 months.
Outcomes: Grip strength, iliopsoas strength, back extensor strength were measured with dynamometers. Static balance was measured using the one-legged standing test while patients were on a stabilometer. The balance was assessed under conditions with the eyes open and with the eyes closed. The dynamic postural balance was assessed while patients completed the functional reach test, as well as with patients seated on a device which collected data on the center of pressure. Functional performance on the 10-meter walk test and the timed up-and-go (TUG) test was also measured.
Methods: RCT; Assessor-blind
Time: Patients were assessed after 6 months of treatment.
What were the important findings?
What should I remember most?
How will this affect the care of my patients?
The authors responsible for this critical appraisal and ACE Report indicate no potential conflicts of interest relating to the content in the original publication.